Nutex Health, Inc. (NUTX) financial statements and ratios from SEC XBRL: revenue $875.26M (TTM), net margin 8.1%, revenue growth 82.4% YoY, P/E 5.5. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $875.26M |
| Net Margin | 8.1% |
| Revenue Growth (YoY) | 82.4% |
| EPS Growth (YoY) | 8.8% |
| FCF Growth (YoY) | 1077.9% |
| P/E Ratio | 5.5 |
| EV / EBITDA | 2.5 |
| Price / Book | 2.52 |
| Price / Sales | 1.40 |
| FCF Yield | 33.8% |
| DCF Value (model) | $924.74 |
| DCF Upside vs Price | 395.9% |
| Altman Z-Score | 3.58 (safe) |
| Sector P/E (Technology) | 33.9 |
NUTX overview · NUTX earnings · NUTX KPIs · NUTX investor relations · NUTX ownership · NUTX peers · NUTX filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.